[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543361":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":7,"responsibleParty":17,"collaborators":19,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":28,"acronym":29,"eligibilityCriteria":30,"healthyVolunteers":25,"sex":31,"minAge":32,"maxAge":7,"enrollmentInfo":33,"targetDuration":7,"studyType":36,"phases":7,"briefSummary":37,"conditions":38,"keywords":7,"overallStatus":40,"whyStopped":7,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":7},{"fullName":5,"class":6},"Neuronostics Ltd","INDUSTRY",null,[9],{"name":10,"affiliation":5,"role":11},"Milaana Mainstone","STUDY_DIRECTOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+44 (0)117 457 2292","m.mainstone@neuronostics.com",{"type":18,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[20],{"name":21,"class":22},"Cornwall Partnership NHS Foundation Trust","NETWORK","100543361","a-study-to-assess-utility-of-bioep-as-an-early-prognostic-indicator-for-predicting-anti-seizure-medication-asm-efficacy-100543361",false,"NCT06354868","A Study to Assess utiLity of BIoEP as an Early Prognostic Indicator for Predicting Anti-Seizure Medication (ASM) Efficacy","A Prospective Observational Clinical Study to Investigate the Relationship Between Seizure Frequency and BioEP During ASM Titration in Newly Diagnosed Patients With Epilepsy, and to Assess the Utility of BioEP as an Early Prognostic Indicator of Anti-seizure Medication (ASM) Efficacy","ECLIPSE","Inclusion Criteria:\n\n* Adult (age 18 and above) presenting with first suspected seizure(s).\n* Able to give informed consent.\n* Patient has received an initial epilepsy diagnosis.\n* Patient accepts decision to commence ASM.\n* Have an EEG prior to commencing ASMs.\n* Participants under watchful waiting who subsequently return to clinic for an epilepsy diagnosis (following a second seizure or a positive EEG) can be included in the study. They must have had an EEG performed in the 12 months prior to be being included in the study (to be used as a baseline EEG) and not have been taking any ASMs at the time.\n\nExclusion Criteria:\n\n* Participants unable to tolerate an EEG test so no EEG data were gathered.\n* Participants with a known hepatic\u002Frenal encephalopathy.\n* Patient diagnosed with possible NEAD and epilepsy (dual diagnosis).\n* Participants taking part in another Clinical Trial of an Investigational Medicinal Product (CTIMP) (qualitative\u002Fobservational studies are acceptable).\n* Patient receiving low does ASMs for other conditions (migraines etc).","ALL","18 Years",{"count":34,"type":35},158,"ESTIMATED","OBSERVATIONAL","This multisite prospective clinical study is to investigate the relationship between seizure type and frequency with the BioEP result during ASM titration in newly diagnosed patients with epilepsy, and to assess the utility of BioEP as an early prognostic indicator of ASM efficacy",[39],"Epilepsy","NOT_YET_RECRUITING","2024-08-12",{"date":43,"type":44},"2024-08-13","ACTUAL",{"date":46,"type":35},"2024-09",{"date":48,"type":35},"2027-06",{"name":5,"class":6}]